Particularly, the double stimulation of anti-CTLA-4 and anti-PD-1 therapy to improve the immune system can help inhibit the proliferation and liver metastasis of colon cancer cells, and the progression-free survival (PFS) and median survival of patients increase by approximately 37% (36). The gene discussed is CTLA4; the disease is malignant colon neoplasm.